Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive Recruiting Phase 1 / 2 Trials for Bosutinib (DB06616)

IndicationStatusPhase
DBCOND0029923 (Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive)Recruiting1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02311998Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CMLTreatment